2019-11-01T14:52:08-05:00 2018-12-31 221430039 SOBEL & CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2018-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2019-11-01 1 BRIDGET HARTNETT P01429163 9739949494 2019-10-11 96.225.92.15 2019-11-01 13:56:06 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 4C84F2E4754EDABD1601D80A9BA97309DA3F6D80 2018 2020-03-31 21:24:44Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 1656325 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH 9 8 5 12 0 0 1715498 1418138 0 0 4719 11326 272647 45143 1992864 1474607 1032334 530333 0 0 397833 398057 0 0 186286 334133 298236 1764300 1226626 228564 247981 2712789 2945938 17181 2349 2695608 2943589 X "SKC IMPACTS CHILDREN IN THE SHORT-TERM THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS.TO ACCOMPLISH OUR MISSION, SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS. " 0 0 981284 530333 SKC AND ITS ADVISORS SURVEY THE PEDIATRIC CANCER LANDSCAPE (PATIENT'S AND RESEARCH) TO UNDERSTAND AND PRIORITIZE THE GREATEST UNMET NEEDS AND DEVELOP PROGRAMS TO ADDRESS THEM. (1) SKC TAKES A GLOBAL APPROACH TO CURES (2) PRIORITY AND FOCUS ONLY ON LOWEST SURVIVAL CHILDHOOD CANCERS INCLUDING HIGH RISK SOLID TUMORS AND BRAIN TUMORS. (3) GO BEYOND FUNDING RESEARCH TO PATIENT CENTRIC APPROACH HELP DELIVER SOLUTIONS TO CHILDREN (4) UNDERTAKE A COALITION APPROACH TO OUR MISSION BECAUSE CHILDHOOD CANCER IS COMPLEX. WE OPENLY WORK WITH MULTIPLE STAKEHOLDERS IN PARTNERSHIP TOWARDS OUR MISSION. SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE STANDARDS-OF-CARE. EVEN IN THE AGE OF RAPID GENOMIC PROFILING, ALL NEWLY DIAGNOSED CHILDREN WITH HIGH RISK CANCERS UNDERGO THE SAME "ONE-SIZE FITS ALL" TREATMENT PROTOCOL DESPITE HAVING DIFFERENT PREDICTED PROGNOSES AND MUTATIONS. SKC IS WORKING WITH STAKEHOLDERS TO HELP THEM IMPROVE CURRENT CLINICAL TRIAL STRUCTURES SO THAT NEWLY DIAGNOSED CHILDREN HAVE MORE TREATMENT PROTOCOLS OPTIONS MATCHED TO THEIR PROGNOSIS/ TO CUSTOMIZATION WHICH WOULD MATCH THE RIGHT PROTOOCOL FOR THE RIGHT RISK/PROGNOSIS. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE,NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, NOVEL/SYNERGISTIC COMBINATION TREATMENTS, NEW TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL THERAPY DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE SKC HAS HELPED TO DEVELOP 27 CLINICAL TRIALS FOR CHILDREN RESULTING IN 25 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS AND 10 PRECLINICAL DEVELOPMENT PROJECTS. 2018 INCLUDED ADDITIONAL PROJECTS TESTING NOVEL COMBINATION AGENTS FOR THE HIGH RISK BRAIN TUMOR ETMR AND A NEW PLATFORM FOR TESTING A MENU OF THERAPEUTIC OPTIONS TO INFORM SUBSEQENUT TREATMENT CHILDREN WITH MEDULLOBLASTOMA USING ORGANOTYPIC SLICE CULTURES. 981284 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 5 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 146560 0 16260 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 HEARN JAY CHO MD DIRECTOR 2.00 X 0 0 0 CHANNING STAVE PHD SECRETARY 2.00 X X 0 0 0 MARK SAVOYE DIRECTOR 2.00 X 0 0 0 MICHAEL NIEDZIELSKI DIRECTOR 2.00 X 0 0 0 EYAL SOFFER TREASURER 2.00 X X 0 0 0 JULIA ROUX DIRECTOR 2.00 X 0 0 0 CATHERINE LONDON DIRECTOR 2.00 X 0 0 0 146560 0 16260 1 0 1 0 0 383811 1034327 1418138 11326 11326 226861 383811 181718 45143 45143 1474607 0 0 56469 357333 357333 173000 173000 162820 162820 200854 77993 37180 85681 9458 6273 280 2905 24925 16054 275 8596 39564 25717 3956 9891 120960 71009 4602 45349 3689 2173 335 1181 7999 4566 703 2730 6414 4170 642 1602 48364 31437 4836 12091 8920 8015 130 775 4861 3160 486 1215 6049 3932 605 1512 FILM EXPENSES 40000 26001 3998 10001 MISCELLANEOUS 5845 3731 576 1538 DUES AND SUBSCRIPTIONS 3759 2443 376 940 MEALS AND ENTERTAINMENT 1812 1457 76 279 1226626 981284 59056 186286 405761 154139 2234550 2721410 36720 40596 26777 22373 229552 225717 5396 3835 3585 3585 2712789 2945938 17181 2349 17181 2349 X 1377572 1214106 1318036 1729483 2695608 2943589 2712789 2945938 247981 0 X X 0 1 X 1 0 X 1381381 761768 1198351 1715498 1418138 6475136 1381381 761768 1198351 1715498 1418138 6475136 194952 6280184 5638 5202 4821 4719 11326 31706 6506842 0.96520 0.95370 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 5160 0 224392 220557 3835 3835 X 1474607 0 1474607 0 1474607 1226626 0 1226626 0 1226626 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2018 AND 2017. AT DECEMBER 31, 2018 AND 2017, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. 1 0 0 0 0 0 0 0 0 0 NORTH AMERICA CANCER RESEARCH 23000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 150000 CHECK 0 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. SPRING CELEBRATION 574588 347727 226861 98196 19451 52144 SEPTEMBER CAMPAIGN 22048 22048 6171 2 14036 14036 5756 610672 383811 226861 98196 19451 64071 181718 45143 1 BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 333333 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3615 CIVIC CENTER BLVD 142-B PHILADELPHIA PA 191044318 231352166 501(C)(3) 24000 CASH CANCER RESEARCH PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 146560 0 0 0 0 0 0 0 0 16260 146560 16260 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION A, LINE 2 JOHN AND CATHERINE LONDON ARE MARRIED. CATHERINE LONDON WAS A BOARD MEMBER THROUGH JUNE 2018. FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARKET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS IS MADE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR.